MIT researchers described a degradable cyclic amino ionizable lipid nanoparticle (LNP) that delivered an influenza mRNA vaccine in mice at roughly 1/100th the dose required by current FDA‑approved materials, generating comparable immune responses. The particle, AMG1541, emerged from combinatorial chemistry and screening and improved endosomal escape and biodegradability. Results published in Nature Nanotechnology showed the LNP achieved equivalent luciferase and immune readouts at far lower mRNA mass, suggesting lower manufacturing cost-per-dose and potentially reduced reactogenicity. LNPs are the delivery vehicle for mRNA therapeutics; design of ionizable lipids controls endosomal release and biodegradability. Translating potency and safety from mice to humans will require further preclinical and clinical work, but the platform may materially lower mRNA vaccine dose requirements if validated.